DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Actoxumab
Actoxumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Where Do Novel Drugs of 2016 Fit In?
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Recurrent Clostridioides Difficile Infection by Disrupting the Mouth for 10 Days Followed by Rifaximin Normal Colonic Microbiota
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
761046Orig1s000
AHRQ Healthcare Horizon Scanning System – Status Update
IX Updating Course of Antimicrobials and Infectious Diseases
(INN) for Biological and Biotechnological Substances
A Replicating Single-Cycle Adenovirus Vaccine Effective Against Clostridium Difficile
Monoclonal Antibodies As an Antibacterial Approach Against Bacterial Pathogens
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Exotoxin Targeted Drug Modalities
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
(INN) for Biological and Biotechnological Substances
Blocking Borrelia Burgdorferi Transmission from Infected Ticks to Nonhuman Primates with a Human Monoclonal Antibody
Top View
Antibiotic-Associated Diarrhea and Clostridioides Difficile Infection 1819
International Nonproprietary Names for Pharmaceutical Substances (INN)
WAGNER-DISSERTATION-2017.Pdf
INN-Nimet 1 27.11.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
OFIL ILAPHAR-31-1.Pdf
ZINPLAVA, INN-Bezlotoxumab
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Development of Neutralizing and Non-Neutralizing Antibodies Targeting Known and Novel Epitopes of Tcdb of Clostridioides Difficile
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
New FDA Approved Antibacterial Drugs: 2015-2017
New Medications and FDA Updates 2016
Standouts Melanoma Drug Yervoy, with Seemingly Better Tolerability
Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria
New Drug Update
Developments in Therapy with Monoclonal Antibodies and Related Proteins
761046Orig1s000